文献速递肾小球疾病

IgA肾病治疗:一个快速发展的领域

Treatment of IgA Nephropathy: A Rapidly Evolving Field.
PubMed 文献 · J Am Soc Nephrol · 2023-09-29

本文综述IgA肾病治疗进展,指出循环IgA免疫复合物结合系膜细胞是关键病理事件,治疗需个体化。目标导向支持治疗是所有患者基石,SGLT2抑制剂和sparsentan应纳入当代支持治疗。全身糖皮质激素用于高危患者但获益有限且毒性大,靶向治疗如靶向释放布地奈德、抗B细胞策略和选择性补体抑制前景可期。

要点

  • 目标导向支持治疗是所有IgA肾病患者的基础,无论进展风险高低。
  • SGLT2抑制剂和sparsentan应作为当代支持治疗的重要组成部分,尤其对慢性肾损伤患者。
  • 全身糖皮质激素适用于高危患者,但撤药后获益减弱且治疗相关毒性显著。

核心结论

  • IgA肾病治疗需个体化,目标导向支持治疗是基石,SGLT2抑制剂和sparsentan应纳入支持治疗,靶向治疗前景可期。

研究设计与样本

  • 综述,检索范围未明确报告。

主要发现

  • 循环含IgA免疫复合物结合系膜细胞是IgA肾病关键病理事件,继发肾小球和肾小管间质炎症与纤维化。
  • 临床参数(蛋白尿程度、持续镜下血尿、eGFR下降速率)联合MEST-C评分是目前识别进展高危患者的最佳方法。
  • 全身糖皮质激素用于高危患者,但撤药后获益减弱且治疗相关毒性显著。
  • 靶向释放布地奈德最受关注,抗B细胞策略和选择性补体抑制可能证明其附加价值。

关键数值与推荐

  • SGLT2抑制剂和sparsentan应纳入当代支持治疗,尤其对慢性肾损伤患者。
  • 全身糖皮质激素适用于高危患者。
  • 靶向释放布地奈德、抗B细胞策略和选择性补体抑制是新兴治疗方向。

临床怎么用

  • 所有患者接受目标导向支持治疗,高危患者考虑全身糖皮质激素但需权衡毒性。
  • 使用临床参数联合MEST-C评分识别进展高危患者,以指导免疫抑制治疗决策。
  • 关注新兴靶向治疗如靶向释放布地奈德、抗B细胞策略和选择性补体抑制的应用价值。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The pivotal event in the pathophysiology of IgA nephropathy is the binding of circulating IgA-containing immune complexes to mesangial cells, with secondary glomerular and tubulointerstitial inflammation and fibrosis. The paramount difficulty in the management of IgA nephropathy is the heterogeneity in its clinical presentation and prognosis, requiring an individualized treatment approach. Goal-directed supportive care remains the bedrock of therapy for all patients, regardless of risk of progression. Sodium-glucose transporter 2 inhibitors and sparsentan should be integral to contemporary supportive care, particularly in patients with chronic kidney damage. Pending the development of reliable biomarkers, it remains a challenge to identify patients prone to progression due to active disease and most likely to derive a net benefit from immunosuppression. The use of clinical parameters, including the degree of proteinuria, the presence of persistent microscopic hematuria, and the rate of eGFR loss, combined with the mesangial hypercellularity, endocapillary hypercellularity, segmental glomerulosclerosis, tubular atrophy/interstitial fibrosis, crescents score, is currently the best approach. Systemic glucocorticoids are indicated in high-risk patients, but the beneficial effects wane after withdrawal and come at the price of substantial treatment-associated toxicity. Therapies with direct effect on disease pathogenesis are increasingly becoming available. While targeted-release budesonide has garnered the most attention, anti-B-cell strategies and selective complement inhibition will most likely prove their added value. We propose a comprehensive approach that tackles the different targets in the pathophysiology of IgA nephropathy according to their relevance in the individual patient.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. El Karoui K, Fervenza FC, De Vriese AS, et al. Treatment of IgA Nephropathy: A Rapidly Evolving Field. J Am Soc Nephrol. 2023. PMID: 37772889. doi:10.1681/ASN.0000000000000242

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。